U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H24N6O5S2.H2O4S
Molecular Weight 626.682
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFQUINOME SULFATE

SMILES

OS(O)(=O)=O.[H][C@]12SCC(C[N+]3=C4CCCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C5=CSC(N)=N5)C([O-])=O

InChI

InChIKey=KYOHRXSGUROPGY-OFNLCGNNSA-N
InChI=1S/C23H24N6O5S2.H2O4S/c1-34-27-16(14-11-36-23(24)25-14)19(30)26-17-20(31)29-18(22(32)33)13(10-35-21(17)29)9-28-8-4-6-12-5-2-3-7-15(12)28;1-5(2,3)4/h4,6,8,11,17,21H,2-3,5,7,9-10H2,1H3,(H3-,24,25,26,30,32,33);(H2,1,2,3,4)/b27-16-;/t17-,21-;/m1./s1

HIDE SMILES / InChI
Cefquinome is a 4th generation cephalosporin which is active against a broad spectrum of Gram positive and Gram negative bacteria. As many cephalosporin it acts by binding to bacterial PBP and thus inhibiting the cell wall synthesis. Cefquinome is approved for veterinary use in cattles with respiratory tract infections, skin infections, bacterial mastitis and septicaemia.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
COBACTAN

Approved Use

Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia.

Launch Date

2006
Curative
COBACTAN

Approved Use

Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia.

Launch Date

2006
Curative
COBACTAN

Approved Use

Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia.

Launch Date

2006
Curative
COBACTAN

Approved Use

Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia.

Launch Date

2006
Curative
COBACTAN

Approved Use

Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia.

Launch Date

2006
Curative
COBACTAN

Approved Use

Treatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia.

Launch Date

2006
PubMed

PubMed

TitleDatePubMed
Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin.
1991 Jan
Patents

Sample Use Guides

1 mg cefquinome/kg (2ml/50 kg body wt.) or 2 mg cefquinome/kg (4ml/50 kg body wt.) given by intramuscular injection (2,5% Cobactan solution).
Route of Administration: Intramuscular
In Vitro Use Guide
The MICs of cefquinome against single laboratory strains of gram-positive and gram-negative anaerobic bacteria were determined. The values were (MIC50): 0.781 ug/ml for Staphylococcus aureus (Methicillin susceptible); 12.5 ug/ml for Staphylococcus aureus (Methicillin resistant); <0.006 ug/ml for Streptococcus spp.; 4.0 ug/ml for Enterococci; 0.049 ug/ml for E.Coli and Klebsiella spp.; 0.098 ug/ml for Salmonella spp., Enterobacter spp. and Proteus mirabilis; 0.195 ug/ml for Serratia marcescens and Proteus spp.; 0.002 ug/ml for Streptococcus pyogenes; 0.008 ug/ml for Streptococcus pneumoniae and Klebsiella pneumoniae; 0.078 ug/ml for Pasteurella multocida, Proteus mirabilis ATCC 14273; 0.03 ug/ml for Escherichia coli 078 and 0.06 ug/ml for Salmonella typhimurium MZ II.
Name Type Language
CEFQUINOME SULFATE
MART.   MI   USAN  
USAN  
Official Name English
CEFQUINOME SULFATE [MART.]
Common Name English
HR111V-SULFATE
Code English
CEFQUINOME SULFATE [USAN]
Common Name English
CEFQUINOME SULFATE [MI]
Common Name English
QUINOLINIUM, 1-((7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-5,6,7,8-TETRAHYDRO-, HYDROXIDE, INNER SALT, (6R-(6.ALPHA.,7.BETA.(Z)))-, SULFATE (1:1)
Common Name English
QUINOLINIUM, 1-((7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-5,6,7,8-TETRAHYDRO-, HYDROXIDE, INNER SALT, (6R-(6.ALPHA.,7.BETA.(Z)))-, SULPHATE (1:1)
Common Name English
HR-111V-SULFATE
Code English
HR111V-SULPHATE
Common Name English
CEFQUINOME SULPHATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
Code System Code Type Description
PUBCHEM
9577261
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
PRIMARY
ChEMBL
CHEMBL1631107
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
PRIMARY
CAS
118443-89-3
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
PRIMARY
EPA CompTox
DTXSID6048593
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
PRIMARY
SMS_ID
300000023790
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
PRIMARY
MERCK INDEX
m3214
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
PRIMARY Merck Index
FDA UNII
3858K104DQ
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
PRIMARY
NCI_THESAURUS
C81032
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
PRIMARY
USAN
HH-33
Created by admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
PRIMARY